News

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.While the COVID-19 pandemic has led to serious setbacks in progress against tuberculosis (TB) with mortality now rising again after a slow but steady decline before the pandemic, COVID-19 has also demonstrated the feasibility of large-scale investment into the rapid development of urgently needed technologies when political will and a sense of urgency exists. Researchers were working on developing new tests, drugs, and vaccines for TB before the pandemic, including one vaccine candidate currently in advanced clinical trials that was developed by GSK and the Bill & Melinda Gates Foundation. Now, powerful technologies that were employed in the development of vaccines for COVID-19, like messenger ribonucleic acid (mRNA), are starting to be employed against TB, with BioNTech and Pfizer planning trials of an mRNA TB vaccine in the next few months.The World Health Organization (WHO) has published its first-ever list of fungal priority pathogens in response to the expanding geographic range of dangerous fungi due to climate change, the rise in cases of fungal disease during the COVID-19 pandemic, and the growth in resistance of fungal diseases to treatments. The list includes 19 pathogens that have been identified as posing the greatest threat to human health. The goal of publishing the list is to catalyze funding for research into fungal infections, which receives less than 1.5 percent of all funding for infectious diseases, as well as to encourage improvements to the treatment guidelines for these infections.The University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP) recently published a draft of a Coronavirus Vaccines Research and Development Roadmap, a project supported by the Bill & Melinda Gates Foundation and The Rockefeller Foundation, for public review and comment. The roadmap, which builds on lessons learned from the development of successful COVID-19 vaccines, identifies strategies to develop effective vaccines for new COVID-19 variants as well as coronaviruses that have yet to emerge. In particular, the roadmap emphasizes the need for durable, broadly protective vaccines that are simple to deliver and that protect against multiple coronaviruses.

At GHTC, we get to read stories every day about incredible innovations in global health. Most of the technologies we see are inventive, some are revolutionary, and a few are so unusual, one might think they were ripped from the pages of a science fiction novel. Now, we’re testing how well you know these global health technologies with our annual Halloween game: the TRICK or TREATment quiz.For each question, we will present a description of a global health technology. Choose TREATment if you believe this innovation exists. Choose TRICK if you think we are trying to pull one over on you and, instead, the product is still in development or is just a figment of our imagination. 

Interested in more global health innovation news? Every week GHTC scours media reports worldwide to deliver essential global health R&D news and content to your inbox. Sign up now to receive our weekly R&D News Roundup email.Regulators in Zimbabwe have approved long-acting injectable cabotegravir, (CAB-LA), making the country the first in Africa and the third in the world (after Australia and the United States) to approve the drug. The World Health Organization (WHO) called the approval a “crucial step” and noted that it would support the implementation and distribution of the prevention method in the country to maximize impact. WHO previously issued a recommendation for CAB-LA in July that cited its high efficacy in reducing HIV transmission among high-risk individuals.A research team from the University of Cape Town published new findings showing evidence that a cancer drug currently in clinical trials has shown potential in protecting from, curing, and preventing malaria transmission. The investigational drug, sapanisertib, acts by killing the human malaria parasite in the liver, the human host red blood cell, and when it divides sexually within the host red blood cells. This is an incredibly significant finding as the drug exhibits a novel mechanism of action as well as activity against multiple stages of the parasite life cycle. Further research could lead to the development of a critically needed novel malaria drug that contributes to malaria control and elimination efforts as well as addresses drug resistance.The United States provided Gilead Sciences’ antiviral, remdesivir, and Mapp Biopharmaceutical Inc’s experimental antibody drug, MBP134, to Uganda in an effort to help prevent further cases and deaths in the outbreak, which is now the largest outbreak of the Sudan strain of Ebola in over 20 years. Both Ugandan and US government officials noted the need for treatment to protect the lives of health care workers, which is a key step in containment.